Literature DB >> 1718702

Calcium antagonists in secondary prevention after myocardial infarction.

S Persson1.   

Abstract

A reliable theoretical background exists to support a secondary preventive effect of calcium antagonists after myocardial infarction. Recent studies also indicate that positive results can be achieved with diltiazem and, in particular, verapamil, provided that they are not given to patients suffering clinically manifest myocardial failure during the acute phase of the disease. When the results of treatment with verapamil and diltiazem are compared with comparable studies with beta-blockers, there is no convincing difference as to their effect on a reduction in mortality. However, studies on nifedipine have shown a negative trend, indicating that the calcium channel blockers should not be regarded as one entity in this respect.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718702     DOI: 10.2165/00003495-199100422-00009

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II)

Authors: 
Journal:  Am J Cardiol       Date:  1990-10-01       Impact factor: 2.778

2.  European Infarction Study (E.I.S.). A secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality.

Authors: 
Journal:  Eur Heart J       Date:  1984-03       Impact factor: 29.983

3.  Effect of alprenolol on mortality among patients with definite or suspected acute myocardial infarction. Preliminary results.

Authors:  M P Andersen; P Bechsgaard; J Frederiksen; D A Hansen; H J Jürgensen; B Nielsen; F Pedersen; O Pedersen-Bjergaard; S L Rasmussen
Journal:  Lancet       Date:  1979-10-27       Impact factor: 79.321

4.  Verapamil in acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.

Authors: 
Journal:  Eur Heart J       Date:  1984-07       Impact factor: 29.983

5.  Reduction in mortality after myocardial infarction with long-term beta-adrenoceptor blockade. Multicentre international study: supplementary report.

Authors: 
Journal:  Br Med J       Date:  1977-08-13

6.  Controlled trial of sotalol for one year after myocardial infarction.

Authors:  D G Julian; R J Prescott; F S Jackson; P Szekely
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

7.  Beneficial effects of timolol on infarct size and late ventricular tachycardia in patients with acute myocardial infarction.

Authors:  F Roqué; L M Amuchastegui; M A Lopez Morillos; G A Mon; A L Girotti; S Drajer; M Fortunato; E Moreyra; P Tuero; J C Solchaga
Journal:  Circulation       Date:  1987-09       Impact factor: 29.690

8.  One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial.

Authors:  V Hansteen; E Møinichen; E Lorentsen; A Andersen; O Strøm; K Søiland; D Dyrbekk; A M Refsum; A Tromsdal; K Knudsen; C Eika; J Bakken; P Smith; P I Hoff
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-16

9.  Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity.

Authors:  G Olsson; N Rehnqvist; A Sjögren; L Erhardt; T Lundman
Journal:  J Am Coll Cardiol       Date:  1985-06       Impact factor: 24.094

10.  Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1986-07-12       Impact factor: 79.321

View more
  6 in total

Review 1.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

Review 2.  Calcium antagonists during and after myocardial infarction.

Authors:  P Sleight
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

3.  Secondary prevention with calcium antagonists after acute myocardial infarction.

Authors:  J F Hansen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 4.  ACE inhibitors and calcium antagonists in the treatment of congestive heart failure.

Authors:  J F Hansen
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

Review 5.  Cardiovascular benefits of antihypertensive therapy postacute myocardial infarction. Therapeutic considerations.

Authors:  P Sleight
Journal:  Drugs       Date:  1993       Impact factor: 9.546

6.  Attenuation of the ischaemia-induced fall of electrical ventricular fibrillation threshold by a calcium antagonist, diltiazem.

Authors:  J F Aupetit; Q Timour; G Chevrel; J Loufoua-Moundanga; S Omar; G Faucon
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.